Common Contracts
1 similar Licensing and Supply Agreement contracts
Licensing and supply agreement for captisol-enabled, propylene glycol-free melphalanLicensing and Supply Agreement • December 28th, 2020
Ligand Pharmaceuticals Incorporated announces that Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA™ (melphalan) for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with MM, and 2) for the palliative treatment of patients with MM for whom oral therapy is not appropriate.
